ZYDELIG
PeakNDAORALTABLETPriority Review
Approved
Jul 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYDELIG (generic name not provided in data) is an oral small-molecule tablet approved by the FDA on July 23, 2014, for the treatment of Non-Hodgkin Lymphoma and Waldenström Macroglobulinemia. Manufactured by Gilead Sciences, it represents a targeted therapy approach for hematologic malignancies. The product is currently in its peak lifecycle stage, indicating sustained market presence and clinical relevance in oncology.
$0.0BPart D
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
Started Oct 2017
17 enrolled
Non Hodgkin LymphomaFollicular LymphomaIndolent Lymphoma+6 more
Career Relevance
ZYDELIG as a peak-stage specialty oncology product creates opportunities for field-based roles including brand managers, medical science liaisons (MSLs), and hematology-oncology specialist representatives requiring strong clinical knowledge of NHL and rare hematologic malignancies. Career paths emphasize deep disease expertise, physician relationship management in academic cancer centers, and formulary/payer advocacy skills. Currently zero linked job openings are reported, suggesting stable team sizing or potential for recruitment during market transitions.
Worked on ZYDELIG at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.